REGISTERED NUMBER: 08619277 (England and Wales)

Unaudited Financial Statements

for the Year Ended 30 April 2023

for

Medcraft Holdings Limited

Contents of the Financial Statements for the Year Ended 30 April 2023

Company Information
for the Year Ended 30 April 2023

DIRECTORS:	D J Medcraft Mrs L Medcraft
REGISTERED OFFICE:	Brackenwood House Kimbell Road Basingstoke Hampshire RG22 4AT
REGISTERED NUMBER:	08619277 (England and Wales)
ACCOUNTANTS:	Lane Monnington Welton Chartered Accountants Riverside View Basing Road Old Basing Basingstoke Hampshire RG24 7AL

Balance Sheet
30 April 2023

	Notes	30.4.23 £	£	30.4.22 £	£
FIXED ASSETS					
Investments	4		100		100
Investment property	5		3,250,000		-
			3,250,100		100
CURRENT ASSETS					
Debtors	6	180,000		820,000	
Cash at bank		89,674		215,781	
		269,674		1,035,781	
CREDITORS					
Amounts falling due within one year	7	1,778,992		254,043	
NET CURRENT (LIABILITIES)/ASSETS			(1,509,318)		781,738
TOTAL ASSETS LESS CURRENT LIABILITIES			1,740,782		781,838
CAPITAL AND RESERVES					
Called up share capital	9		100		100
Retained earnings			1,740,682		781,738
SHAREHOLDERS' FUNDS			1,740,782		781,838

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 April 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 April 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Balance Sheet - continued
30 April 2023

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 13 July 2023 and were signed on its behalf by:

D J Medcraft - Director

1. STATUTORY INFORMATION

Medcraft Holdings Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Financial instruments
Debtors and creditors payable/receivable within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

Loans and borrowings
Loans and borrowings are initially recognised at the transaction price, including transaction costs. Subsequently they are measured at amortised cost using the effective interest rate method, less impairment. If an arrangement constitutes a finance transaction it is measured at present value.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date, adjusted for indexation where applicable.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

2. **ACCOUNTING POLICIES - continued**

Impairment
Assets not measured at fair value are reviewed for any indication that an asset may be impaired at each balance sheet date. The directors review the carrying amount of the relevant assets and compare them to their market values and recoverable amounts. Where the carrying amount exceeds this, an impairment loss is recognised in profit or loss, unless the asset is carried at a revalued amount, where the impairment loss is a revaluation decrease.

3. **EMPLOYEES AND DIRECTORS**

The average number of employees during the year was 2 (2022 - 2) .

4. **FIXED ASSET INVESTMENTS**

	Shares in group undertakings £
COST	
At 1 May 2022	
and 30 April 2023	100
NET BOOK VALUE	
At 30 April 2023	100
At 30 April 2022	100

5. **INVESTMENT PROPERTY**

	Total £
FAIR VALUE	
Additions	3,250,000
At 30 April 2023	3,250,000
NET BOOK VALUE	
At 30 April 2023	3,250,000

6. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	30.4.23 £	30.4.22 £
Trade debtors	180,000	120,000
Other debtors	-	700,000
	180,000	820,000

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.23	30.4.22
	£	£
Amounts owed to group undertakings	100,000	100,000
Taxation and social security	177,271	154,043
Other creditors	1,501,721	-
	1,778,992	254,043

8. SECURED DEBTS

The following secured debts are included within creditors:

	30.4.23	30.4.22
	£	£
Directors' loan account	1,501,721	-

The directors' loan is secured by a charge over the investment property owned by the company.

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number:	Class:	Nominal value:	30.4.23 £	30.4.22 £
100	Ordinary	£1	100	100

10. SHARE OPTION SCHEME

The company operates a share option plan for selected employees of the group. The options vest on the occurrence of a sale of the company and may be exercised with in the period beginning with the date of sale and ending 30 days thereafter and shall lapse and cease to be exercisable at the end of that period.

If the options remain unexercised after a period of 10 years from the date of grant, the options expire. Options may not be exercised if the employee leaves the group before the options vest except where the Board permits it under certain clauses or the employment terminates for certain reasons.

In 2021 the company granted an employee an option to purchase 33 Ordinary shares with an exercise price of £19,000 per share. These options expire in August 2029.